Company intelligence / Profile preview
Rapa Therapeutics
Rockville , Maryland, United Statesmassgeneral.org ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Rapa’s lead program RAPA‑501 is an autologous epigenetically reprogrammed TREG/Th2 “hybrid” cell therapy showing safety and biological activity in ALS patients with trends toward slowing pulmonary decline. Their oncology program uses non-genetically engineered rapamycin-resistant Th1/Tc1 cells. Early clinical results include stringent complete remissions in multiple myeloma patients refractory to other treatments. The company’s approach aims to provide less toxic alternatives compared to existing immunotherapies.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Autologous T cell therapies (including rapamycin-resistant T cells)Adoptive cell therapyImmunomodulators
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Supported by TEDCO Venture Funds ($1M investment)collaboration with Sean M. Healey & AMG Center for ALS at Mass General Hospitalpartial support from the ALS Association
Beyond the preview
Go deeper on Rapa Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rapa Therapeutics.